Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing
Stocks in this Quantisnow insightHealth Care
Historical context for SCNI
Across the 20 sessions after earlier SCNI headlines, the stock closed higher 11 times and lower 9 times, with a median move of 5.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SCNI | SPY |
|---|---|---|---|
| Oct 16, 2026 | Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement | -16.5% | -1.1% |
| Oct 14, 2026 | Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement | -28.5% | -1.1% |
| Oct 13, 2026 | Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement | +6.0% | -0.0% |
| Sep 21, 2026 | Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement | +8.3% | +1.6% |
| Sep 8, 2026 | Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business | -8.6% | -0.5% |
| Aug 24, 2026 | Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum | -2.8% | -0.3% |
Keep researching SCNI
Quantisnow market dataNASDAQ
SCNI
Scinai Immunotherapeutics Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2015
Get push alerts for SCNI
Full SCNI profile on Quantisnow Follow SCNI and get a push notification the moment its next story breaks.